Candida endocarditis

Candida endocarditis

mycotic endocarditis caused by a species of Candida. Also called endocardial candidiasis.
Mentioned in ?
References in periodicals archive ?
sup][5] Treatment guidelines for native valve Candida endocarditis strongly recommended surgical treatment within 1 week, combined with antifungal treatment consisting of liposomal amphotericin B or caspofungin for 6-8 weeks, with or without additional flucytosine, followed by fluconazole.
Candidiasis moniliasis, thrush, candida paronychia, candida endocarditis, bronchomycosis, mycotic vulvovaginitis, candiosis.
141 Mortality for Candida endocarditis is high (67%), with a lower mortality in younger patients with a history of IV drug use.
parapsilosis endocarditis in one series of Candida endocarditis cases.
The clinical presentation of Candida endocarditis is non-specific.
9] Individual case reports have shown successful medical treatment of Candida endocarditis using the echinocandins without surgical intervention;[14-16] however, there is insufficient experience with these agents to make a recommendation for medical management alone.
Of 34 patients with Candida endocarditis (13 definite and 21 possible), 7 were OHCA with an increasing trend when compared with those with IHCA candidemia (Table 2).
Therapy for Candida endocarditis consists of amphotericin B plus flucytosine and early surgery; long-term suppression with an oral azole is advised.
The use of these drugs may represent an important step in the treatment of invasive systemic Candida infections by enhancing retention of affected intravascular devices and obviating the need for valve surgery in Candida endocarditis (2,19,29).